The rationale for sympathetic modulation in NIDDM and the insulin resistance syndrome

Reviews in Contemporary Pharmacotherapy

Volumn 9, Issue 7, 1998, Pages 429-439

  Rösen, Peter ^a   Rösen, Renate ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; MOXONIDINE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ADRENERGIC SYSTEM; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; DYSLIPIDEMIA; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; SKELETAL MUSCLE; SYMPATHETIC NERVE; SYNDROME X; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031686631     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Anand BK, China GS, Shram KN, Dua S, Singh B. Activity of single neurons in the hypothalamic feeding centres: effect of glucose. Am J Physiol 1964; 207: 1146-1154.
2. + channels. Pflügers Arch 1990; 415: 479-483.
3. Baron AD. Hemodynamic actions of insulin. Am J Physiol 1994; 267: E187-E202.
4. Björntorp P. Obesity and diabetes mellitus. In: Porte D, Sherwin RS, eds. Ellenbergs and Rifkin's Diabetes mellitus. Stamford: Appleton and Lange, 1997: 553-564.
5. Camus JP. Groute, diabete, hyperlipémie. Un trisyndrome métabolique. Rév Rhumatisme 1966; 33: 10-14.
6. Chaturvedi N, McKeigue PM, Marmot MG. Relationships of glucose intolerance to coronary risk in Afro-Caribbeans compared to Europeans. Diabetologia 1994; 37: 765-772.
7. DeFronzo RA. Insulin resistance, hyperinsulinemia, and coronary artery disease: a complex metabolic web. J Cardiovasc Pharmacol 1992; 20 (Suppl 11): S1-S16.
8. DeFronzo RA. Diabetic renal disease. In: Porte D, Sherwin RS, eds. Ellenbergs and Rifkin's Diabetes mellitus. Stamford: Appleton and Lange, 1997: 971-1008.
9. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
10. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium and phosphate in man. J Clin Invest 1975; 75: 845-855.
11. Despres JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 1993; 9: 452-459.
12. Despres JP, Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol 1994; 5: 274-289.
13. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Borchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10: 497-511.
14. Despres JP, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
15. Donnelly R, Connell JMC. Insulin resistance: possible role in the aetiology and clinical course of hypertension. Clin Sci 1992; 83: 265-275.
16. 1-imidazoline receptor agonist moxonidine: molecular, cellular and organismic actions. Rev Contemp Pharmacother 1998; 9:441-462.
17. 1-imidazoline agonist. Cardiovasc Drugs Ther 1994; 8 (Suppl 1): 27-41.
18. Ernsberger P, Koletsky RJ, Collins LA, Bedol D. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent. Cardiovasc Drugs Ther 1996; 10 (Suppl 1): 275-282.
19. 1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J Hypertens 1997; 15: (Suppl 1): S9-S23.
20. Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance and essential hypertension. N Engl J Med 1987; 317: 350-357.
21. Ferrannini E, Natal A. Essential hypertension, metabolic disorders, and insulin resistance. Am Heart J 1991; 121: 1274-1282.
22. Ferrari P, Weidmann P, Shaw S et al. Altered insulin sensitivity, hyperinsulinemia and dyslipidemia in individuals with a hypertensive parent. Am J Med 1991; 91: 589-596.
23. Fontbonne A. Epidemiological data on hyperinsulinemia and vascular disease. Diabetes Metab Rev 1993; 9: 135-175.
24. Fontbonne A. Why can high insulin indicate a risk for coronary heart disease? Diabetologia 1994; 37: 953-955.
25. Frayn KN, Coppack SW. Insulin resistance, adipose tissue, and coronary heart disease. Clin Sci 1992; 82: 1-8.
26. Frei M, Küster L, Gardosch-von Krosigk P-P, Koch HF, Küppers H. Moxonidine and hydrochlorothiazide and combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994; 24 (Suppl 1): S25-S26.
27. Gregoire JR, Sheps SG. Newer antihypertensive drugs. Curr Opin Cardiol 1995; 110: 445-449.
28. Gwynne J. Clinical features and pathophysiology of familial dyslipidemic hypertension syndrome. Curr Opin Lipidol 1992; 3: 215-221.
29. Hall JE, Brands MW, Kivlighn SD, Mizelle HL, Hildebrandt DA, Gailard CA. Chronic hyperinsulinemia and blood pressure: interactions with catecholamines? Hypertension 1990; 15: 519-527.
30. Hall JE, Brands MW, Zappe DH, Alonso-Galicia M. Insulin resistance, hyperinsulinemia, and hypertension: causes, consequences, or merely correlations? Proc Soc Exp Biol Med 1995; 208: 317-329.
31. Hanefeldt M, Leonhardt W. Das metabolische Syndrom. Dtsch Gesundh Wesen 1980; 36: 545-551.
32. 1-imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1994; 24 (Suppl 1): S1-S8.
33. Henriksen EJ, Jacobs S, Fogt OL, Youngblood EB, Godicke J. The antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats. Hypertension 1997; 30: 1560-1565.
34. Hollenbeck C, Reaven GM. Variants in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol 1987; 64: 1169-1175.
35. Himsworth HP. Diabetes mellitus: a differentiation into insulin-sensitive and insulin-insensitive types. Lancet, 1936; i: 127-130.
36. Holman GD, Kasuga M. From receptor to transporter: insulin signaling to glucose transport. Diabetologia 1997; 40: 991-1003.
37. Hwang IS, Ho H, Hoffmann BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987; 10: 512-516.
38. Jahnke K, Daweke H, Liebermeister H et al. Hormonal and metabolic aspects of obesity in man. In: Östmann J, ed. Diabetes. Proc Sixth Congr International Diabetes Federation. Amsterdam: Excerpta Medica Foundation, 1969: 533-539.
39. Kaan CE, Brückner R, Frohly P, Tupl M, Schäfer SG, Ziegler D. Effects of agmatine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1994; 5 (Suppl 1): 19-27.
40. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979a; 241: 2035-2038.
41. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors. The Framingham study. Circulation 1979b; 1: 8-13.
42. Kannel WB, Wilson PWF, Zhang TJ. The epidemiology of impaired glucose tolerance and hypertension. Am J Med 1991; 91: 1268-1273.
43. Kaplan NM. The deadly quartet. Upper-body obesity, glucose tolerance, hypertriglyceridemia, and hypertension. Arch Int Med 1989; 149: 1514-1520.
44. Karhapää P, Voutilainen H, Kovanen PT, Laasko M. Insulin resistance in familial and nonfamilial hypercholesterolemia. Arterioscler Thromb 1993; 13: 41-47.
45. Kjeldsen SE, Rostrup M, Moan A, Mundal HH, Gjesdal K, Eide IK. The sympathetic nervous system may modulate the metabolic cardiovascular syndrome in essential hypertension. J Cardiovasc Pharmacol 1992; 20 (Suppl 8): S32-S39.
46. Kobayashi R, Nagano M, Nakamura F et al. Role of angiotensin II in high fructose-induced left ventricular hypertrophy in rats. Hypertension 1993; 21: 1051-1055.
47. Koletsky RJ, Ernsberger P. Obese SHR (Koletsky rat): a rat model for the interactions between hypertension and obesity. Colloq INSERM 1992; 218: 373-375.
48. Koopmanns SJ, Ohman L, Haywood JR, Mandarino LJ, DeFronzo RA. Seven days of euglycemic hyperinsulinemia induces insulin resistance for glucose metabolism, but not hypertension, elevated catecholamine levels, or increased sodium retention in conscious normal rats. Diabetes 1997; 46: 1572-1578.
49. Küster L, Koch HF. A randomised, double blind, placebo-controlled, parallel group study to determine the efficacy, dose response and safety of moxonidine in the treatment of essential mild to moderate hypertension. Kali-Chemie AG, Report K 220.5027, 1993.